Skip to main content
SpringerLink
Log in

Bone-Directed Therapy and Breast Cancer: Bisphosphonates, Monoclonal Antibodies, and Radionuclides

  • Chapter
  • First Online:
Breast Disease

  • 867 Accesses

Abstract

Breast cancer bone metastasis causes severe morbidity and is commonly encountered in daily clinical practice. It causes pain, pathologic fractures, spinal cord, and other nerve compression syndromes and life-threatening hypercalcemia. Breast cancer metastasizes to the bone through a complicated process that involves numerous molecules. Metastatic cells disrupt normal bone turnover and create a vicious cycle. All treatment effort is directed to breaking this vicious cycle. Bisphosphonates have been used safely for more than two decades. As a group, bisphosphonates delay the time to the first skeletal-related event and reduce pain. However, they do not prevent the development of bone metastasis in patients with no bone metastasis and do not prolong survival. The receptor activator for nuclear factor κB ligand inhibitor denosumab also delays the time to the first skeletal-related event and reduces the skeletal morbidity rate. Radionuclides are another treatment option for bone pain.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55(1):61–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989;8(2):98–101.

    CAS  PubMed  Google Scholar 

  3. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337–42.

    Article  CAS  PubMed  Google Scholar 

  4. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309–19.

    Article  CAS  PubMed  Google Scholar 

  5. Ohshiba T, Miyaura C, Ito A. Role of prostaglandin E produced by osteoblasts in osteolysis due to bone metastasis. Biochem Biophys Res Commun. 2003;300(4):957–64.

    Article  CAS  PubMed  Google Scholar 

  6. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone. 2003;32(1):1–7.

    Article  CAS  PubMed  Google Scholar 

  7. Kayamori K, Sakamoto K, Nakashima T, Takayanagi H, Morita K, Omura K, et al. Roles of interleukin-6 and parathyroid hormone-related peptide in osteoclast formation associated with oral cancers: significance of interleukin-6 synthesized by stromal cells in response to cancer cells. Am J Pathol. 2010;176(2):968–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Mazo IB, von Andrian UH. Adhesion and homing of blood-borne cells in bone marrow microvessels. J Leukoc Biol. 1999;66(1):25–32.

    Article  CAS  PubMed  Google Scholar 

  9. Bussard KM, Gay CV, Mastro AM. The bone microenvironment in metastasis; what is special about bone? Cancer Metastasis Rev. 2008;27(1):41–55.

    Article  PubMed  Google Scholar 

  10. van der P, Vloedgraven H, Papapoulos S, Lowick C, Grzesik W, Kerr J, et al. Attachment characteristics and involvement of integrins in adhesion of breast cancer cell lines to extracellular bone matrix components. Lab Inv J Tech Methods Pathol. 1997;77(6):665–75.

    Google Scholar 

  11. Pecheur I, Peyruchaud O, Serre CM, Guglielmi J, Voland C, Bourre F, et al. Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J Off Publ Fed Am Soc Exp Biol. 2002;16(10):1266–8.

    CAS  Google Scholar 

  12. Pishvaian MJ, Feltes CM, Thompson P, Bussemakers MJ, Schalken JA, Byers SW. Cadherin-11 is expressed in invasive breast cancer cell lines. Cancer Res. 1999;59(4):947–52.

    CAS  PubMed  Google Scholar 

  13. Guise TA. Parathyroid hormone-related protein and bone metastases. Cancer. 1997;80(8 Suppl):1572–80.

    Article  CAS  PubMed  Google Scholar 

  14. Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE, Klagsbrun M. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J Biol Chem. 1986;261(27):12665–74.

    CAS  PubMed  Google Scholar 

  15. Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun. 2005;328(3):679–87.

    Article  CAS  PubMed  Google Scholar 

  16. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int J Established Results Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2008;19(6):733–59.

    Article  CAS  Google Scholar 

  17. Russell RG. Bisphosphonates: the first 40 years. Bone. 2011;49(1):2–19.

    Article  CAS  PubMed  Google Scholar 

  18. Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48(4):677–92.

    Article  CAS  PubMed  Google Scholar 

  19. Frith JC, Monkkonen J, Auriola S, Monkkonen H, Rogers MJ. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum. 2001;44(9):2201–10.

    Article  CAS  PubMed  Google Scholar 

  20. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res Off J Am Soc Bone and Miner Res. 1998;13(4):581–9.

    Article  CAS  Google Scholar 

  21. van Holten-Verzantvoort AT, Bijvoet OL, Cleton FJ, Hermans J, Kroon HM, Harinck HI, et al. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet. 1987;2(8566):983–5.

    Article  PubMed  Google Scholar 

  22. Elomaa I, Blomqvist C, Porkka L, Holmstrom T, Taube T, Lamberg-Allardt C, et al. Clodronate for osteolytic metastases due to breast cancer. Biomed Pharmacother Biomed Pharmacother. 1988;42(2):111–6.

    CAS  PubMed  Google Scholar 

  23. Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 1993;11(1):59–65.

    Article  CAS  Google Scholar 

  24. Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med. 1999;246(1):67–74.

    Article  CAS  PubMed  Google Scholar 

  25. Tubiana-Hulin M, Beuzeboc P, Mauriac L, Barbet N, Frenay M, Monnier A, et al. Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull Cancer. 2001;88(7):701–7.

    CAS  PubMed  Google Scholar 

  26. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol Off J Am Soc Clin Oncol. 1998;16(6):2038–44.

    Article  CAS  Google Scholar 

  27. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol Off J Am Soc Clin Oncol. 1999;17(3):846–54.

    Article  CAS  Google Scholar 

  28. Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88(5):1082–90.

    Article  CAS  PubMed  Google Scholar 

  29. Hultborn R, Gundersen S, Ryden S, Holmberg E, Carstensen J, Wallgren UB, et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Anticancer Res. 1999;19(4c):3383–92.

    CAS  PubMed  Google Scholar 

  30. Conte PF, Latreille J, Mauriac L, Calabresi F, Santos R, Campos D, et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol Off J Am Soc Clin Oncol. 1996;14(9):2552–9.

    Article  CAS  Google Scholar 

  31. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J (Sudbury Mass). 2001;7(5):377–87.

    CAS  Google Scholar 

  32. Rosen LS, Gordon DH, Dugan W Jr, Major P, Eisenberg PD, Provencher L, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004;100(1):36–43.

    Article  CAS  PubMed  Google Scholar 

  33. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98(8):1735–44.

    Article  CAS  PubMed  Google Scholar 

  34. Body JJ, Diel IJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2003;14(9):1399–405.

    Article  Google Scholar 

  35. Heras P, Kritikos K, Hatzopoulos A, Georgopoulou AP. Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. Eur J Cancer Care. 2009;18(6):653–6.

    Article  CAS  Google Scholar 

  36. Body JJ, Diel IJ, Lichinitzer M, Lazarev A, Pecherstorfer M, Bell R, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer. 2004;90(6):1133–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Palmieri C, Fullarton JR, Brown J. Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19(24):6863–72.

    Article  CAS  Google Scholar 

  38. O’Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N, Goodwin A. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 2017;10:CD003474.

    PubMed  Google Scholar 

  39. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(35):5132–9.

    Article  CAS  Google Scholar 

  40. Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, et al. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol. 2013;14(7):663–70.

    Article  CAS  PubMed  Google Scholar 

  41. Hortobagyi GN, Van Poznak C, Harker WG, Gradishar WJ, Chew H, Dakhil SR, et al. Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial. JAMA Oncol. 2017;3(7):906–12.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, et al. Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA. 2017;317(1):48–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(28):4431–7.

    Article  CAS  Google Scholar 

  44. Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(9):1221–7.

    Article  CAS  Google Scholar 

  45. Morris PG, Lynch C, Feeney JN, Patil S, Howard J, Larson SM, et al. Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(19):3154–9.

    Article  Google Scholar 

  46. Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, et al. Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update. J Clin Oncol. 2017;35(35):3978–86.

    Article  CAS  PubMed  Google Scholar 

  47. Clemons M, Dranitsaris G, Ooi W, Cole DE. A phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. Breast Cancer Res Treat. 2008;108(1):79–85.

    Article  CAS  PubMed  Google Scholar 

  48. Clemons MJ, Dranitsaris G, Ooi WS, Yogendran G, Sukovic T, Wong BY, et al. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(30):4895–900.

    Article  CAS  Google Scholar 

  49. Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(10):1564–71.

    Article  CAS  Google Scholar 

  50. Cleeland CS, Body JJ, Stopeck A, von Moos R, Fallowfield L, Mathias SD, et al. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid. Cancer. 2013;119(4):832–8.

    Article  CAS  PubMed  Google Scholar 

  51. Hoff AO, Toth B, Hu M, Hortobagyi GN, Gagel RF. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients. Ann N Y Acad Sci. 2011;1218:47–54.

    Article  CAS  PubMed  Google Scholar 

  52. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res Off J Am Soc Bone and Miner Res. 2008;23(6):826–36.

    Article  CAS  Google Scholar 

  53. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2012;23(5):1341–7.

    Article  CAS  Google Scholar 

  54. Hirschberg R. Renal complications from bisphosphonate treatment. Curr Opin Support Palliat Care. 2012;6(3):342–7.

    Article  PubMed  Google Scholar 

  55. Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol JASN. 2001;12(6):1164–72.

    CAS  PubMed  Google Scholar 

  56. Sauter M, Julg B, Porubsky S, Cohen C, Fischereder M, Sitter T, et al. Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept? Am J Kidney Dis Off J Natl Kidney Found. 2006;47(6):1075–80.

    Article  Google Scholar 

  57. Berenson JR, Boccia R, Lopez T, Warsi GM, Argonza-Aviles E, Lake S, et al. Results of a multicenter open-label randomized trial evaluating infusion duration of zoledronic acid in multiple myeloma patients (the ZMAX trial). J Support Oncol. 2011;9(1):32–40.

    Article  CAS  PubMed  Google Scholar 

  58. Sun L, Yu S. Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: a systematic review and meta-analysis. Am J Clin Oncol. 2013;36(4):399–403.

    Article  CAS  PubMed  Google Scholar 

  59. Peter R, Mishra V, Fraser WD. Severe hypocalcaemia after being given intravenous bisphosphonate. BMJ (Clin Res Ed). 2004;328(7435):335–6.

    Article  Google Scholar 

  60. Chennuru S, Koduri J, Baumann MA. Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid. Intern Med J. 2008;38(8):635–7.

    Article  CAS  PubMed  Google Scholar 

  61. Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer (Oxf Engl: 1990). 2012;48(16):3082–92.

    Article  CAS  Google Scholar 

  62. Aapro M, Abrahamsson PA, Body JJ, Coleman RE, Colomer R, Costa L, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2008;19(3):420–32.

    Article  CAS  Google Scholar 

  63. Pazianas M, Abrahamsen B. Safety of bisphosphonates. Bone. 2011;49(1):103–10.

    Article  CAS  PubMed  Google Scholar 

  64. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2006;17(6):897–907.

    Article  CAS  Google Scholar 

  65. Wilkinson GS, Baillargeon J, Kuo YF, Freeman JL, Goodwin JS. Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(33):4898–905.

    Article  CAS  Google Scholar 

  66. Anastasilakis AD, Toulis KA, Goulis DG, Polyzos SA, Delaroudis S, Giomisi A, et al. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res Hormon- und Stoffwechselforschung Horm Metab. 2009;41(10):721–9.

    Article  CAS  Google Scholar 

  67. Tomblyn M. The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases. Cancer Control J Moffitt Cancer Cent. 2012;19(2):137–44.

    Article  CAS  Google Scholar 

  68. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369(3):213–23.

    Article  CAS  PubMed  Google Scholar 

  69. Suominen MI, Rissanen JP, Kakonen R, Fagerlund KM, Alhoniemi E, Mumberg D, et al. Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis. J Natl Cancer Inst. 2013;105(12):908–16.

    Article  PubMed  Google Scholar 

  70. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001;357(9253):336–41.

    Article  CAS  PubMed  Google Scholar 

  71. Oosterhof GO, Roberts JT, de Reijke TM, Engelholm SA, Horenblas S, von der Maase H, et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol. 2003;44(5):519–26.

    Article  CAS  PubMed  Google Scholar 

  72. Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63(5):940–5.

    Article  PubMed  Google Scholar 

  73. Fuster D, Herranz D, Vidal-Sicart S, Munoz M, Conill C, Mateos JJ, et al. Usefulness of strontium-89 for bone pain palliation in metastatic breast cancer patients. Nucl Med Commun. 2000;21(7):623–6.

    Article  CAS  PubMed  Google Scholar 

  74. Baczyk M, Czepczynski R, Milecki P, Pisarek M, Oleksa R, Sowinski J. 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nucl Med Commun. 2007;28(4):245–50.

    Article  PubMed  Google Scholar 

  75. Sciuto R, Festa A, Pasqualoni R, Semprebene A, Rea S, Bergomi S, et al. Metastatic bone pain palliation with 89-Sr and 186-re-HEDP in breast cancer patients. Breast Cancer Res Treat. 2001;66(2):101–9.

    Article  CAS  PubMed  Google Scholar 

  76. Kasalicky J, Krajska V. The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med. 1998;25(10):1362–7.

    Article  CAS  PubMed  Google Scholar 

  77. Sartor O, Reid RH, Bushnell DL, Quick DP, Ell PJ. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer. 2007;109(3):637–43.

    Article  CAS  PubMed  Google Scholar 

  78. Englaro EE, Schroder LE, Thomas SR, Williams CC, Maxon HR 3rd. Safety and efficacy of repeated sequential administrations of Re-186(Sn)HEDP as palliative therapy for painful skeletal metastases. Initial case reports of two patients. Clin Nucl Med. 1992;17(1):41–4.

    Article  CAS  PubMed  Google Scholar 

  79. Hiscox S, Barrett-Lee P, Borley AC, Nicholson RI. Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss. Eur J Cancer (Oxf Engl: 1990). 2010;46(12):2187–95.

    Article  CAS  Google Scholar 

  80. Vandyke K, Dewar AL, Farrugia AN, Fitter S, Bik To L, Hughes TP, et al. Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia. 2009;23(5):994–7.

    Article  CAS  PubMed  Google Scholar 

  81. Hannon RA, Finkelman RD, Clack G, Iacona RB, Rimmer M, Gossiel F, et al. Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a phase I study. Bone. 2012;50(4):885–92.

    Article  CAS  PubMed  Google Scholar 

  82. Jensen AB, Wynne C, Ramirez G, He W, Song Y, Berd Y, et al. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clin Breast Cancer. 2010;10(6):452–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Faculty of Medicine, Balkan Oncology Hospital, Trakya University of Medicine, Edirne, Turkey

    Bulent Erdogan & Irfan Cicin

Authors
  1. Bulent Erdogan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Irfan Cicin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bulent Erdogan .

Editor information

Editors and Affiliations

  1. Oncology Institute, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey

    Adnan Aydiner

  2. Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey

    Abdullah Igci

  3. Division of Surgical Oncology, Department of Surgery, University of Pittsburgh School of Medicine, Magee-Women’s Hospital of UPMC, Pittsburgh, PA, USA

    Atilla Soran

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Erdogan, B., Cicin, I. (2019). Bone-Directed Therapy and Breast Cancer: Bisphosphonates, Monoclonal Antibodies, and Radionuclides. In: Aydiner, A., Igci, A., Soran, A. (eds) Breast Disease. Springer, Cham. https://doi.org/10.1007/978-3-030-16792-9_42

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-16792-9_42

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-16791-2

  • Online ISBN: 978-3-030-16792-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation